Clinical Trial Detail

NCT ID NCT02027961
Title Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors MedImmune LLC
Indications

melanoma

Therapies

Dabrafenib + Durvalumab + Trametinib

Durvalumab + Trametinib

Age Groups: adult senior

Additional content available in CKB BOOST